SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Depotech(depo)
DEPO 7.300+1.7%Aug 14 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (862)11/16/1998 6:33:00 PM
From: John McCarthy   of 887
 
Here's how the market was described 2 years ago ... from IBD.

"We have assumed the DC wil gain 30% (U.S.) market share of
previously treated patients in 1997, escalating to
80% by the year 2000.

Today, only 30% of americans with NM - or about 20,000 -
are treated each year. Many patients and their doctors,
finding that existing drugs scarely work, simply choose not to
pursue further treatment.

Analysts though, believe DC will greatly expand the market.
..... Also, it might be used as a preventive measure for
patients who do not have NM but are at high risk of getting
it, the UBS report said. "

You can change the year 1997 to 1998 and the year 2000 to 2001.

In addition, I have lost material that I had talking about
DC being used for Head & Neck cancer.

Regards,
John McCarthy
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News